These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7538548)

  • 1. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
    Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR
    J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
    D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
    Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
    J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
    Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
    J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
    J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
    J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
    Johnson VA
    J Infect Dis; 1995 Mar; 171 Suppl 2():S140-9. PubMed ID: 7861019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
    Welles SL; Jackson JB; Yen-Lieberman B; Demeter L; Japour AJ; Smeaton LM; Johnson VA; Kuritzkes DR; D'Aquila RT; Reichelderfer PA; Richman DD; Reichman R; Fischl M; Dolin R; Coombs RW; Kahn JO; McLaren C; Todd J; Kwok S; Crumpacker CS
    J Infect Dis; 1996 Oct; 174(4):696-703. PubMed ID: 8843205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
    Coombs RW; Welles SL; Hooper C; Reichelderfer PS; D'Aquila RT; Japour AJ; Johnson VA; Kuritzkes DR; Richman DD; Kwok S; Todd J; Jackson JB; DeGruttola V; Crumpacker CS; Kahn J
    J Infect Dis; 1996 Oct; 174(4):704-12. PubMed ID: 8843206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
    Boucher CA; O'Sullivan E; Mulder JW; Ramautarsing C; Kellam P; Darby G; Lange JM; Goudsmit J; Larder BA
    J Infect Dis; 1992 Jan; 165(1):105-10. PubMed ID: 1370174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.
    Shafer RW; Winters MA; Jellinger RM; Merigan TC
    J Infect Dis; 1996 Aug; 174(2):448-9. PubMed ID: 8699089
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
    Conlon CP; Klenerman P; Edwards A; Larder BA; Phillips RE
    J Infect Dis; 1994 Feb; 169(2):411-5. PubMed ID: 7508970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.